Q&A: Page 5
Exclusive interviews with industry leaders
-
Novo Nordisk’s quantum bet on ‘world changing’ computing
Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.
Taren Grom • Nov. 10, 2022 -
The other ‘D’ in DE&I
How companies can work to include people with disabilities into broader equity aims.
Taren Grom • Nov. 4, 2022 -
Tuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that
The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.
Alexandra Pecci • Nov. 1, 2022 -
The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology
Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.
Karissa Waddick • Oct. 27, 2022 -
Nobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development
The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.
Karissa Waddick • Oct. 26, 2022 -
He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma
Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.
Michael Gibney • Oct. 17, 2022 -
Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses
President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.
Kelly Bilodeau • Oct. 13, 2022 -
Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology
The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.
Meagan Parrish • Oct. 12, 2022 -
Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets
CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.
Karissa Waddick • Oct. 11, 2022 -
New partnership may give MDMA an edge in the psychedelics space
While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses.
Kelly Bilodeau • Oct. 10, 2022 -
Her antibiotic company failed. Now she’s helping others avoid the same fate.
The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.
Karissa Waddick • Oct. 6, 2022 -
It’s electric — speeding up the cell therapy process for scalability
To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.
Alexandra Pecci • Oct. 4, 2022 -
Clinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that
The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.
PharmaVoice staff • Oct. 3, 2022 -
Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut
Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.
Michael Gibney • Oct. 3, 2022 -
Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success
The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression.
Meagan Parrish • Sept. 27, 2022 -
Why precision medicine could be the next frontier in treating autism
Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.
Kelly Bilodeau • Sept. 27, 2022 -
That’s not Angry Birds — that’s your doctor learning about novel drugs through gaming
How pharma companies can teach physicians about mechanism of action and other medication lessons with interactive mobile games.
Alexandra Pecci • Sept. 26, 2022 -
First 90 Days: Agios Pharmaceuticals’ Brian Goff
The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.
Alexandra Pecci • Aug. 22, 2022 -
How real world evidence is impacting rare disease drug development
ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.
Kim Ribbink • Aug. 9, 2022 -
A glimpse inside Bristol Myers Squibb’s integration with Celgene
Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.
Meagan Parrish • Aug. 1, 2022 -
How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond
WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.
Kim Ribbink • Aug. 1, 2022 -
Personalized data could bring PhysIQ to the forefront of clinical trial evolution
The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.
Karissa Waddick • July 28, 2022 -
Lupus discovery lends clues to the fight against long COVID
So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.
Kelly Bilodeau • July 27, 2022 -
Behind Pfizer's new quest to target a 'transformation' in pharma
A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.
Kelly Bilodeau • July 25, 2022 -
Anjarium Biosciences’ CEO on its next-gen gene therapies
Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.
Kim Ribbink • July 15, 2022